These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1268 related items for PubMed ID: 25444922

  • 1. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):971-7. PubMed ID: 25444922
    [Abstract] [Full Text] [Related]

  • 2. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A.
    Int J Cancer; 2013 Oct 01; 133(7):1732-42. PubMed ID: 23505071
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 01; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L, Li G, Zhu H, Dong X, Zhao D, Jiang X, Li J, Qiao H, Ni S, Sun X.
    Cancer Lett; 2014 Dec 01; 355(1):96-105. PubMed ID: 25218350
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
    Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A.
    Anticancer Res; 2013 Apr 01; 33(4):1415-20. PubMed ID: 23564781
    [Abstract] [Full Text] [Related]

  • 9. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun 01; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 10. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y, Sun L, Fu Y, Huang Y, Zhou R, Hu X, Zhou P, Quan J, Li N, Fan XG.
    BMC Cancer; 2017 Dec 15; 17(1):857. PubMed ID: 29246127
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 15; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 12. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 15; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 13. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX, Shi WN, Song ZY, Wang SQ, Yu XF, Gao ZH, Qu XJ.
    Oncotarget; 2016 Jun 14; 7(24):36767-36782. PubMed ID: 27167344
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
    Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F.
    Mol Cancer Ther; 2012 Oct 14; 11(10):2284-93. PubMed ID: 22902857
    [Abstract] [Full Text] [Related]

  • 15. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Tsai JJ, Hsu FT, Pan PJ, Chen CW, Kuo YC.
    Anticancer Res; 2018 Apr 14; 38(4):2119-2125. PubMed ID: 29599330
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
    Nojiri K, Sugimoto K, Shiraki K, Tameda M, Inagaki Y, Ogura S, Kasai C, Kusagawa S, Yoneda M, Yamamoto N, Takei Y, Nobori T, Ito M.
    Int J Oncol; 2013 Jan 14; 42(1):101-8. PubMed ID: 23123700
    [Abstract] [Full Text] [Related]

  • 17. Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
    Lange M, Abhari BA, Hinrichs TM, Fulda S, Liese J.
    Biochem Pharmacol; 2016 Oct 15; 118():9-17. PubMed ID: 27544320
    [Abstract] [Full Text] [Related]

  • 18. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
    Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, Yang PC, Cheng AL.
    Int J Cancer; 2014 Jan 15; 134(2):319-31. PubMed ID: 23818246
    [Abstract] [Full Text] [Related]

  • 19. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ, Choi YK, Park SY, Jang SY, Lee JY, Ham HJ, Kim BG, Jeon HJ, Kim JH, Kim JG, Lee IK, Park KG.
    Mol Cancer Res; 2017 Sep 15; 15(9):1230-1242. PubMed ID: 28584024
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH, Feng WC, Lu LC, Shao YY, Hsu CH, Cheng AL.
    Cancer Lett; 2016 Oct 10; 381(1):58-66. PubMed ID: 27431312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.